Debating Modern Medical Technologies: The Politics of Safety, Effectiveness, and Patient Access
Autor Karen J. Maschke, Michael K. Gusmanoen Limba Engleză Hardback – 13 sep 2018 – vârsta până la 17 ani
Preț: 307.62 lei
Preț vechi: 359.27 lei
-14% Nou
Puncte Express: 461
Preț estimativ în valută:
58.86€ • 62.16$ • 48.99£
58.86€ • 62.16$ • 48.99£
Carte tipărită la comandă
Livrare economică 13-27 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781440861895
ISBN-10: 1440861897
Pagini: 232
Dimensiuni: 156 x 235 x 17 mm
Greutate: 0.57 kg
Editura: Bloomsbury Publishing
Colecția Praeger
Locul publicării:New York, United States
ISBN-10: 1440861897
Pagini: 232
Dimensiuni: 156 x 235 x 17 mm
Greutate: 0.57 kg
Editura: Bloomsbury Publishing
Colecția Praeger
Locul publicării:New York, United States
Caracteristici
Helps readers to understand the political, economic, and ideological dimensions of disputes about health technology assessment and the implications of various policy approaches for patients and the health care system
Notă biografică
Karen J. Maschke is research scholar at the Hastings Center with expertise on the ethical, legal, and policy issues associated with new biomedical technologies. She is editor of IRB: Ethics & Human Research.Michael K. Gusmano is associate professor of health policy at Rutgers University and research scholar at the Hastings Center with expertise on the politics of health reform, comparative politics, and health technology assessment.
Cuprins
AcknowledgmentsChapter 1 Evidence, Politics, and Medical Care TechnologyChapter 2 Evolving Public- and Private-Payer Approaches to Evidence and Health Technology AssessmentChapter 3 Mammography Screening: Vested Interests and PolarizationChapter 4 When Medicare Said No for Amyloid PET ImagingChapter 5 Placing a Value on Cure: Lessons from the New Generation of Hepatitis C DrugsChapter 6 Avastin and the Politics of Accelerated ApprovalChapter 7 The Path to the Clinic for Stem Cell and Other Regenerative Medicine InterventionsChapter 8 Conclusion: The 21st Century Cures Act and the Future of Health Technology AssessmentNotesBibliographyIndex